# Ipamorelin FAQ: Common Questions, Cited Answers > Ipamorelin FAQ: clear, cited answers on what it is, how it works, whether it is selective, the risks, the failed trial, and the CJC-1295 combination questions. Definitions, mechanism, risks, and the combination questions — each answer direct and cited where it makes a number claim. ## What is ipamorelin? Ipamorelin is a synthetic five-amino-acid peptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and a selective ghrelin-receptor (GHS-R1a) agonist. In its founding characterization it released growth hormone potently in rat cells, rats, and swine — a swine ED50 of 2.3 nmol/kg — without raising ACTH or cortisol, making it the first selective growth hormone secretagogue [1]. It is not an approved drug. ## What does ipamorelin do for you? In the research, ipamorelin triggers a discrete pulse of growth hormone by selectively activating the ghrelin receptor, with minimal effect on cortisol or prolactin [1]. People in research-use communities most often report better sleep and faster recovery, but those are anecdotal. The one human outcome trial, for postoperative ileus, failed [3], so no proven human benefit has been established. ## What is ipamorelin peptide? Ipamorelin peptide is a wholly synthetic pentapeptide — five amino acids strung in the order Aib-His-D-2-Nal-D-Phe-Lys-NH2, with a molecular weight near 712 daltons. It mimics the body's ghrelin to activate the GHS-R1a receptor and release growth hormone selectively [1]. It was developed in the 1990s and is sold only as a research chemical, never approved as a medicine [3]. ## How does CJC-1295 ipamorelin work? The pairing hits two complementary levers. CJC-1295 is a GHRH analog acting on the GHRH receptor; ipamorelin is a GHS-R1a (ghrelin-receptor) agonist acting through a separate calcium-driven pathway [1]. Because ghrelin-side agonists also suppress somatostatin, the GH brake, the two routes amplify each other in the underlying neuroendocrine literature [7]. No controlled trial has tested the combination itself [3]. ## Is ipamorelin selective for growth hormone? Yes — that is its defining feature. In the 1998 founding study, ipamorelin released GH as potently as GHRP-6 but did not raise ACTH or cortisol above baseline, even at doses more than 200-fold above its GH threshold [1]. A swine study independently confirmed the selective GH-release profile [8]. It is described in the literature as the first selective growth hormone secretagogue [1]. ## What are the risks of ipamorelin? The honest answer is that long-term human risk is uncharacterized. The only Phase 2 trial recorded adverse events in 87.5% of the ipamorelin arm versus 94.8% of placebo over up to 7 days, with no ipamorelin-specific signal in that brief window [3]. A 28-day study of a related ghrelin-receptor agonist found dose-dependent heart-muscle damage in rats — a class-level signal, not an ipamorelin finding [6]. No long-term safety database exists. ## Does ipamorelin reduce belly fat? There is no human trial showing ipamorelin reduces belly fat. In animals, it affects body composition: a 2024 ferret study found it blunted chemotherapy-driven weight loss by about 24% during the delayed phase [5], and an ipamorelin-derived oral analog drove body-weight gain in rats [11]. Community reports of a gradual leaner look are anecdotal and confounded by diet and training — not a clinical finding. ## What are the downsides of ipamorelin? Beyond reported side effects like facial flushing, more hunger, and mild puffiness, the substantive downside is the evidence gap: ipamorelin has no approved indication and its one Phase 2 trial failed its primary endpoint [3]. There is a class-level cardiac signal from a related agonist over 28 days [6], no long-term human data, and unregulated supply of unverified purity. The marketing far outpaces the proof. ## Why is ipamorelin being discontinued? Ipamorelin's clinical development effectively stopped because its only Phase 2 trial, for postoperative ileus, missed its primary endpoint — time to first tolerated meal was 25.3 hours versus 32.6 hours on placebo (p=0.15) [3] — and no Phase 3 followed. Separately, in 2024 the FDA removed ipamorelin acetate from Category 2 of the interim 503A bulk-substances list, tightening compounding-pharmacy access. ## What does CJC-1295 and ipamorelin do? Together they aim to raise growth hormone through two complementary pathways: CJC-1295 amplifies the GHRH signal, while ipamorelin adds a selective ghrelin-receptor signal that suppresses the GH brake somatostatin and stimulates GH release [7][1]. The neuroendocrine rationale is sound, but no controlled trial has tested the combination for sleep, recovery, body composition, or any other outcome [3]. ## Does ipamorelin increase IGF-1? Not consistently in short studies. Ipamorelin releases growth hormone, which can drive the liver to make IGF-1 — but in the 15-day rat bone-growth study, total IGF-1 did not change even as bone growth increased, pointing to a partly local GH-pulse effect rather than a sustained IGF-1 rise [4]. Whether sustained human protocols would raise IGF-1 has not been characterized in controlled trials. ## How much CJC-1295 ipamorelin should I take? No published human study establishes a dose for the CJC-1295 plus ipamorelin combination, so there is no evidence-based answer and this digest does not provide one [3]. The controlled human ipamorelin record consists only of intravenous, clinic-administered protocols [2][3]. Community "stack" doses circulating online are anecdotal, rest on single-agent pharmacology, and have no controlled-trial basis [7]. ## Does CJC-1295 ipamorelin work? The mechanism is genuine — pairing a GHRH analog with a GHS-R1a agonist hits two complementary GH-release levers that synergize in the neuroendocrine literature [7]. But "works" cannot be confirmed from combination data, because no trial has tested the pairing for any outcome [3]. Reported benefits like better sleep are anecdotal. The honest position: a sound rationale, no combination evidence. ## How to reconstitute CJC-1295 ipamorelin 5mg? As a general research-handling matter, ipamorelin is supplied as a lyophilized (freeze-dried) powder and reconstituted with bacteriostatic water, then kept refrigerated because peptides degrade with heat and freeze-thaw. That is a handling observation, not a clinical preparation instruction, and no specific volume is endorsed here. No published human protocol exists for a CJC-1295 plus ipamorelin preparation [3]. ## How long does ipamorelin stay in your system? In healthy human volunteers, ipamorelin showed a terminal half-life of approximately 2 hours by the intravenous route, with the growth-hormone pulse peaking about 40 minutes after dosing [2]. As a rough rule, a drug is largely cleared after several half-lives, so ipamorelin's measurable presence is short-lived — though anti-doping laboratories can still detect growth hormone secretagogues by dedicated urine methods. ## Does ipamorelin make you hungry? Some users report increased hunger in the hours after injecting, which fits the mechanism — ipamorelin activates the ghrelin (hunger) receptor [1]. Community accounts generally call it milder than the hunger from older peptides like GHRP-6, but real enough to matter for anyone watching intake. This is an occasionally-reported, anecdotal effect, not a measured outcome from a human trial. ## Will I gain weight on ipamorelin? No human trial answers this. In animals, ipamorelin-class compounds alter body composition — an ipamorelin-derived oral analog produced significant body-weight gain in rats over 14 days [11], and ipamorelin blunted weight loss in a ferret cachexia model [5]. Any human weight change would be confounded by appetite effects, diet, and training, and is not established by controlled data. Reported effects are anecdotal. ## Does ipamorelin increase appetite? It can, by mechanism: ipamorelin activates GHS-R1a, the ghrelin receptor that governs appetite [1], and increased hunger is an occasionally-reported community effect. A 2026 critical review of peptide use in sport notes the GH-axis risks of this class in uncontrolled use [9]. Community accounts describe the appetite bump as milder than with GHRP-6 — but it is an anecdotal observation, not a measured trial endpoint. ## What does ipamorelin peptide do? Ipamorelin peptide selectively activates the ghrelin receptor (GHS-R1a) on pituitary cells, triggering a discrete growth-hormone pulse with minimal cortisol or prolactin [1]. Downstream, growth hormone can raise IGF-1, though not consistently in short studies [4]. In humans, the one outcome trial it was tested in — for bowel recovery after surgery — failed [3], so its proven human effects are limited to the pharmacology, not a therapeutic result. ## How long does it take for ipamorelin to work? Pharmacologically, fast: the growth-hormone pulse peaks about 40 minutes after an intravenous dose in humans, with a roughly 2-hour half-life [2]. That is the GH response, not a wellness outcome. Community reports of sleep improvements often describe the first one to two weeks, but those are anecdotal and unverified — no controlled human trial has measured a time-to-effect for any wellness endpoint. ## Does ipamorelin cause water retention? Mild water retention and puffiness — in fingers, ankles, or face during the first few weeks — is an occasionally-reported community effect, generally described as milder than with older GH-releasing peptides and tending to ease with continued use. It is biologically plausible because growth-hormone excess is linked to sodium and water retention, but it is an anecdotal report here, not a measured finding from a controlled ipamorelin trial [3]. ## Where to inject CJC-1295 ipamorelin? This digest does not give injection instructions. For context only: in the research literature the dominant route for this peptide class is subcutaneous, and the controlled human ipamorelin studies used the intravenous route in a clinic setting [2][3]. There is no published human protocol for self-administering a CJC-1295 plus ipamorelin combination [3], and nothing here should be read as guidance on how or where to inject anything. --- A forward-looking read of the ipamorelin literature, led by the one trait the molecule does cleanly — a selective GH pulse with the cortisol and prolactin left out — and honest about where the human evidence still runs thin; a reading instrument, not a clinic, a prescription, or a store.